Hepatomegaly: What it is, echo signs, and treatment

Hepatomegaly is a symptom, not a diagnosis in itself: the liver is larger than the age and constitutional norm, based on examination and/or imaging. In adults, it is suspected by palpation and percussion, but is confirmed only by measurements (ultrasound, tomography, or magnetic resonance imaging), as a "large liver to the touch" alone is not accurate enough. The normal "length" of the liver in adults varies, and without instrumental assessment, it is easy to be mistaken in either direction. [1]

The causes of hepatomegaly are varied, ranging from metabolic-associated steatotic liver disease and alcoholic liver disease to viral, autoimmune, and congestive conditions, tumors, and storage diseases. Multiple factors can be present in the same person—for example, obesity plus regular alcohol consumption. Therefore, the approach always begins with an etiologic search, rather than an attempt to "treat liver size." [2]

The clinical significance of hepatomegaly depends on the cause and accompanying symptoms. Rapid liver enlargement with fever and jaundice indicates inflammation or obstruction, while painless enlargement indicates infiltration or congestion. The physician evaluates the entire patient's symptoms, physical examination, laboratory markers of the liver's synthetic and excretory functions, and signs of portal hypertension. [3]

Modern technologies are changing diagnostics: noninvasive indices and elastography screen out patients with a low risk of fibrosis, and when necessary, precise methods are used, such as magnetic resonance elastography or quantitative tomography with automatic volume calculation. This reduces the number of unnecessary biopsies and speeds decision-making. [4]

Code according to ICD-10 and ICD-11

In ICD-10, hepatomegaly is classified in the symptom block: R16.0 - "hepatomegaly, not elsewhere classified"; R16.1 - splenomegaly; R16.2 - hepatosplenomegaly. If the cause is established (e.g., fatty infiltration K76.0, viral hepatitis, heart failure), it is coded primarily, and R16.* is used as additional information on the phenotype, when appropriate. [5]

ICD-11 has a separate section ME10 "Hepatomegaly or splenomegaly": ME10.00 - "hepatomegaly, not elsewhere classified"; ME10.01 - splenomegaly; ME10.02 - combined enlargement. ICD-11 also provides "expanding" codes to detail severity, morphology, and context, but, as in ICD-10, if the cause is established, the code for the underlying disease remains primary. [6]

Table 1. Frequently used codes (ICD-10 and ICD-11)

Clinical situation	ICD-10	Comment	ICD-11
Hepatomegaly of unspecified cause	R16.0	Symptom code	ME10.00
Hepatosplenomegaly	R16.2	Symptom code	ME10.02
Splenomegaly	R16.1	Symptom code	ME10.01
Fatty infiltration of the liver	K76.0	A common cause in adults	DB92.0 (MASLD without hepatitis)
Alcoholic liver disease	K70.*	By degree and complications	Alcoholic liver disease block codes

Epidemiology

Hepatomegaly as a symptom occurs in the context of the most common liver diseases. Metabolic-associated steatotic liver disease affects approximately 30% of the adult population worldwide, with rates increasing in recent decades; it is the leading cause of "enlarged liver" in the population. Prevalence is higher in men than in women. [7]

Alcohol-associated liver disease remains the leading cause of cirrhosis worldwide and significantly contributes to mortality and hospital burden. Recent trends indicate a "rejuvenation" of the problem, including an increase in severe forms in young women in some countries. This means that alcohol history should always be carefully assessed in patients with hepatomegaly. [8]

Viral hepatitis, drug-induced liver injury, and liver tumors account for a smaller but clinically significant proportion of cases. Global reviews emphasize the increasing contribution of drug-induced liver injury and the continued importance of viruses in acute hepatitis. These factors often lead to rapid onset of symptoms and require different management. [9]

Hepatosplenomegaly (simultaneous enlargement of the liver and spleen) is more often associated with infiltrative, metabolic, and hematological causes; a recent review suggests a systematic stepwise approach to such patients to avoid missing rare but treatable storage diseases.[10]

Table 2. Prevalence of key underlying conditions

State	Estimated adult prevalence
Metabolic-associated steatotic liver disease	≈30%
Metabolic-associated steatohepatitis (active form)	5-7% of the population (estimates by region)
Significant alcohol consumption with risk of liver damage	Highly variable; high contribution to cirrhosis and death

Reasons

The causes of hepatomegaly are conveniently divided into 6 groups. 1) Metabolic: fat in the liver due to insulin resistance, less often - hereditary metabolic defects. 2) Alcoholic: inflammation and fatty infiltration with regular ethanol consumption. 3) Inflammatory and infectious: viral hepatitis, autoimmune hepatitis, abscesses. 4) Congestive: right ventricular failure, constrictive pericarditis, hepatic vein obstruction. 5) Infiltrative and tumor: lymphomas, leukemia, metastases, primary liver cancer. 6) Medicinal and toxic: from anabolic steroids and herbs to antitumor agents. [11]

Combinations of causes are common. For example, a patient with obesity and moderate alcohol consumption may have a mixed picture of steatohepatitis; in type 2 diabetes, the risk of inflammation and fibrosis is particularly high. Therefore, the medical history should cover diet, alcohol (in grams of ethanol per week), medications, and herbs. [12]

In some patients, hepatomegaly is caused by non-bleeding factors, such as congestion due to heart failure: the liver is enlarged and tender along the edges, with swelling and shortness of breath. The diagnostic "branch" here quickly leads to cardiology. [13]

Finally, hepatosplenomegaly should raise concerns about storage diseases (lysosomal diseases, lysosomal acid lipase deficiency), where enzyme replacement or other targeted therapies are available. Their early recognition improves outcomes. [14]

Table 3. Common causes of hepatomegaly in adults

Category	Examples
Metabolic	MASLD/MASh, Wilson's disease (less common in adults)
Alcoholic	Alcoholic hepatitis and steatosis
Inflammatory/infectious	Viral hepatitis, autoimmune hepatitis, abscesses
Stagnant	Right ventricular failure, venous obstruction
Infiltrative/tumor	Lymphomas, leukemia, metastases, primary cancer
Medicinal/toxic	Anti-tumor, herbs, anabolic steroids

Risk factors

The most important modifiable factors are obesity, insulin resistance, type 2 diabetes mellitus, hypertension, and atherogenic dyslipidemia. These factors underlie metabolic fatty liver disease, which most often underlies hepatomegaly in the population. Controlling these parameters reduces not only liver but also cardiovascular risks. [15]

Regular alcohol consumption above safe limits is an independent risk factor for hepatomegaly, fibrosis, and cirrhosis. In recent years, an increase in severe forms has been observed in certain groups of young people, necessitating active screening and early intervention. [16]

Drug factors include long courses of potentially hepatotoxic drugs (some antibiotics, immunomodulators, herbal remedies). The time-dose-response relationship and the exclusion of alternatives help identify drug-related factors. [17]

Additional non-modifiable factors: age, male gender (for steatosis), family history, genetic variants (PNPLA3, TM6SF2, etc.). They enhance the importance of metabolic and behavioral triggers. [18]

Pathogenesis

In metabolic fatty liver disease, insulin resistance plays a key role. Toxic lipid intermediates accumulate in hepatocytes, mitochondria are damaged, and inflammation and fibrogenesis are triggered. Clinically, this manifests as an increase in liver volume and, as the disease progresses, the development of portal hypertension. [19]

Alcohol induces oxidative stress, impairs fatty acid oxidation, and enhances inflammatory pathways. Repeated injury-repair leads to remodeling and fibrosis, and in the early stages, to liver enlargement due to steatosis and inflammation. [20]

Congestive hepatomegaly develops due to increased venous pressure: the hepatic veins become congested, leaving the liver enlarged and painful. Long-term congestion leads to "cardiac fibrosis," so treatment must address the underlying cause—the heart. [21]

Infiltrative and neoplastic processes enlarge the liver due to cellular infiltration or space-occupying lesions. Here, the organ may be dense, lumpy, and sometimes painless; the laboratory picture differs from that of inflammation. [22]

Symptoms

Hepatomegaly itself may be asymptomatic and is discovered incidentally. With liver enlargement, heaviness or discomfort in the right hypochondrium and early satiety due to capsule distension are often noted. Tenderness at the edge of the liver is typical of congestive and inflammatory causes. [23]

Systemic signs depend on the cause: fever and jaundice indicate inflammation/obstruction; fatigue, itching, and bruising indicate chronic coagulation factor deficiency; weight loss and night sweats indicate a tumor or systemic process. Combinations of symptoms help select the diagnostic "branch." [24]

In metabolic and alcoholic steatosis, symptoms are often sparse; laboratory changes and imaging are decisive. Therefore, in people with risk factors (obesity, type 2 diabetes), hepatomegaly is actively sought and fibrosis is staged. [25]

Special attention is given to hepatosplenomegaly: the addition of an enlarged spleen shifts the probability towards infiltrative, hematological and metabolic causes and dictates a broader search. [26]

Classification, forms and stages

Practical classification divides hepatomegaly into isolated (liver only) and combined (with the spleen). The combined form more often indicates systemic and infiltrative causes. Two other useful signs are consistency (soft with steatosis, firm with fibrosis/infiltration) and tenderness. [27]

Depending on the duration, a distinction is made between acute and chronic liver enlargement. Rapid enlargement suggests infection, obstruction, drug-induced damage, or congestion; slow enlargement suggests metabolic, infiltrative, and neoplastic causes. [28]

Fibrosis is staged separately (from F0 to F4), as it determines the prognosis and monitoring strategy. Noninvasive indices and elastography allow the risk of significant fibrosis to be assessed without biopsy in most patients. [29]

Visualization distinguishes between "diffuse" (uniform) and "local" (due to space-occupying lesions) enlargement. In the case of localized variants, tumors and focal processes are first excluded. [30]

Table 4. Key “axes” of classification in the clinic

Axis	Options	Practical significance
Isolated vs. combined	Liver ± spleen	Systemic/infiltrative causes in combined
Dynamics	Acute vs. chronic	Selecting a diagnostic "branch"
Consistency and soreness	Soft/hard; painful/painless	Steatosis/congestion vs. fibrosis/infiltration
Distribution	Diffuse vs. local	Exclusion of focal process

Complications and consequences

Risks are determined by the underlying cause. In metabolic and alcoholic diseases, these include progression of fibrosis to cirrhosis, portal hypertension, hepatocellular carcinoma, and high cardiovascular risk. It is the degree of fibrosis, not enzyme levels, that best predicts outcomes. [31]

Inflammatory and obstructive causes pose a risk of acute liver failure, cholangitis, and sepsis. Delayed diagnosis worsens the prognosis, so "red flags" require immediate treatment. [32]

Congestive hepatomegaly without correction of heart failure leads to chronic "cardiac" liver fibrosis, nutritional problems, and ascites. Improved hemodynamics often reduces liver size and symptoms. [33]

Infiltrative and neoplastic processes pose a risk of systemic complications and require oncohematological management. Here, the time to diagnosis is particularly critical. [34]

Table 5. Red flags for an enlarged liver

Sign	Possible cause	Actions
Fever + pain in the right hypochondrium + jaundice	Acute hepatitis/cholangitis	Urgent hospitalization, laboratory + ultrasound
Sudden weakness, bleeding, confusion	Liver failure	Emergency care, coagulogram
Rapid belly weight gain, swelling, shortness of breath	Congestive heart failure	Cardiological assessment
Weight loss, night sweats, paleness	Hematology/Oncology	Onco-routing, CT/MRI

When to see a doctor

A liver enlargement detected on ultrasound, even if the patient feels well, is a reason for consultation: the doctor will compare the liver size with normal values and risk factors. Early identification of the cause helps prevent the progression of fibrosis and complications. [35]

Seek immediate medical attention if you experience jaundice, dark urine and light-colored stools, fever without a cold, severe weakness, bleeding, abdominal distension, swelling, or shortness of breath. These signs indicate the threat of liver or cardiac decompensation. [36]

People with obesity, type 2 diabetes, hypertension, and dyslipidemia should undergo routine fibrosis risk stratification, even without symptoms. This includes a simple index and a noninvasive assessment of liver stiffness. [37]

If you are taking potentially hepatotoxic medications or herbal supplements, discuss this with your doctor: some cases of hepatomegaly are drug-related and require a review of therapy. [38]

Diagnostics

The first step is a clinical laboratory screening: liver enzymes, total and direct bilirubin, albumin, international normalized ratio, complete blood count, inflammation markers, glucose, and lipids. Alcohol consumption (in grams per week), medications/dietary supplements, and family and occupational history are also assessed. [39]

The second step is ultrasound as a first-line method. It is safe, accessible, and allows not only for measuring the right lobe (craniocaudally along the midclavicular line), but also for assessing the echostructure (steatosis, fibrosis patterns), bile ducts, and portal blood flow. If there are "echo signs" of steatosis and no duct dilation, the physician proceeds along the "metabolic branch"; if there is dilation, along the "obstructive branch." [40]

The third step is fibrosis risk stratification in patients with probable metabolic or alcoholic disease: a simple index (e.g., FIB-4) and liver elastography. Increased stiffness (usually from ≈8 kPa) suggests significant fibrosis; values from ≈12 kPa indicate advanced stages. Serum fibrosis tests and magnetic resonance elastography are used when indicated. [41]

The fourth step is clarifying imaging. Magnetic resonance imaging or computed tomography are used for focal lesions, unclear anatomy, suspected tumors, or vascular pathology. Modern approaches include automated volume calculation and thresholds for defining hepatomegaly by volume, which is particularly useful in complex anatomy. Liver biopsy is performed in cases of diagnostic uncertainty or for histological verification. [42]

Table 6. Step-by-step diagnostic algorithm

Step	What are we doing?	What do we get?	Next move
1	Laboratory screening + anamnesis	Liver function and risk profile	Selecting a "branch" of probability
2	Ultrasound of the abdominal cavity	Dimensions, echo signs, ducts, portal blood flow	Metabolic vs. obstructive branch
3	Fibrosis index + elastography	Risk of significant fibrosis	Treatment/observation decision
4	MRI/CT (as indicated)	Foci, vessels, volume	Onco-route/interventions/observation
5	Biopsy (if indicated)	Histology, stage	Targeted therapy/tactics

Table 7. Normative benchmarks and echo signs on ultrasound

Parameter	Landmark for an adult	Comment
Right lobe (craniocaudal)	≈13-15 cm (depending on gender and height)	Interpret in accordance with the constitution
Echo signs of steatosis	Increased echogenicity, attenuation, “bright” liver	A common cause of hepatomegaly
Dilation of the ducts	Dilation of the intrahepatic/common bile ducts	The "obstruction" branch
Signs of portal hypertension	Enlargement of the spleen, dilation of the portal vein	Assess fibrosis and its causes

Differential diagnosis

Metabolic vs. alcoholic. Both cause "silent" hepatomegaly and steatosis, but the context is different: predominantly cardiometabolic factors versus significant alcohol consumption. Sometimes they coexist, increasing the risk of fibrosis—this is important to consider when planning treatment and goals. [43]

Inflammatory/obstructive vs. infiltrative. Fever, pain, jaundice, and dilated ducts on ultrasound indicate inflammation or obstruction. A painless, dense liver, weight loss, and systemic symptoms suggest a tumor or infiltration, requiring oncologic imaging. [44]

Congestive vs. hepatic. Congestive symptoms include shortness of breath, edema, distended neck veins, and tenderness of the liver margin; laboratory changes are moderate. Improving cardiac function reduces liver function—the key to diagnosis and treatment. [45]

Hepatosplenomegaly. The presence of a spleen requires the exclusion of storage diseases and hematology. A current review recommends a minimally invasive approach: enzyme and genetic testing before biopsy when the clinical picture is typical. [46]

Treatment

The basic principle: treat the cause, not the "centimeters." At the outset, the severity is assessed—synthetic function (albumin, international normalized ratio), bilirubin, signs of portal hypertension, and complications. Potentially hepatotoxic drugs and supplements are discontinued, and vaccinations against hepatitis A and hepatitis B are administered if necessary. If any "red flags" are detected, hospitalization is promptly initiated. [47]

In metabolic-associated fatty liver disease, the "pillars" are nutrition and exercise. A 7-10% weight loss is associated with a reduction in inflammation, and a 10% or greater weight loss is associated with a reduction in fibrosis. A calorie deficit, limiting added sugars and ultra-processed foods, adequate protein and fiber, 150-300 minutes of moderate aerobic exercise per week, plus 2-3 strength training sessions are recommended. Treatment goals and monitoring are based on fibrosis dynamics, not just enzymes. [48]

Pharmacotherapy for active metabolic disease and fibrosis is guided by current regional approvals and guidelines. Preference is given to agents with proven effects on histology and body weight, as well as medications for diabetes control and atherogenic dyslipidemia with cardiovascular and renal benefits. Noninvasive stratification helps select patients who are expected to benefit most. [49]

For alcoholic liver disease, the key is complete abstinence and a support program for alcohol cessation (medication and psychological support). For alcoholic hepatitis, the treatment strategy is determined by the severity: some patients require glucocorticosteroids and close inpatient monitoring. A multidisciplinary approach (hepatologist, psychiatrist-narcologist, nutritionist) improves outcomes and reduces the risk of relapse. [50]

For viral and autoimmune causes, treatment is etiotropic. Highly effective treatment regimens are available for chronic viral hepatitis, often curing the infection and reducing liver size as fibrosis regresses. Autoimmune hepatitis is treated with immunosuppressants (usually glucocorticosteroids ± azathioprine) with subsequent support, which prevents progression and reduces hepatomegaly. [51]

Congestive hepatomegaly requires cardiac compensation: diuretics to control volume, basic therapy for heart failure, correction of arrhythmias and defects, and nutritional support. As filling pressure normalizes, liver size decreases, and laboratory parameters stabilize. Collaboration between a cardiologist and a hepatologist is essential. [52]

Infiltrative and neoplastic causes are managed according to oncological standards: diagnosis confirmation (biopsy/cytology), staging, systemic therapy, and local interventions (resection, ablation, embolization) as indicated. For hepatocellular carcinoma, combined approaches are used, including systemic targeted therapies and immunotherapy. Early treatment determines the outcome. [53]

Drug-induced cases require discontinuation of the causative agent and supportive therapy. The physician assesses the likelihood of a causal relationship, excludes alternatives, and, if necessary, performs a biopsy to verify the phenotype of the lesion. Re-administration of the suspected drug is contraindicated. [54]

Enzyme and genetic testing are used for hepatosplenomegaly and suspected storage diseases; enzyme replacement and other targeted therapies are available for a number of conditions. Early access to specialized centers allows for stabilization of the liver process and organ reduction. Management is interdisciplinary, with long-term monitoring. [55]

Finally, in advanced fibrosis and cirrhosis, the primary goal is the prevention of complications and timely referral to a transplant center. Programs include liver cancer screening, prevention and treatment of portal hypertension, nutritional modification, and sarcopenia. Liver size at this stage is less informative than liver function and complication status. [56]

Prevention

Prevention focuses on modifiable factors: healthy eating, weight control, regular physical activity, and limiting or abstaining from alcohol. These measures reduce the risk of metabolic and alcoholic liver diseases, the two most common causes of hepatomegaly. [57]

Controlling blood pressure, lipids, and glucose is an essential part of prevention. This also reduces cardiovascular risk, which is the leading cause of death in patients with fatty liver disease. [58]

Vaccination against hepatitis A and B, caution with potentially hepatotoxic drugs, and avoiding uncontrolled use of herbal supplements are also included in "basic liver hygiene." If therapy with risky drugs is necessary, the physician selects regimens with the lowest liver burden and organizes monitoring. [59]

People from risk groups (obesity, type 2 diabetes, combined cardiometabolic factors) benefit from periodic liver check-ups with non-invasive stratification of fibrosis - this is a simple and effective way to “catch” progression in time. [60]

Forecast

The prognosis is determined by the cause and stage of fibrosis. In metabolic liver disease, early lifestyle modifications and modern drug therapy can lead to regression of inflammation and a reduction in liver stiffness, which reduces the risk of decompensation and cancer. In alcohol-related liver disease, sustained abstinence remains key. [61]

Inflammatory causes (viral, autoimmune) often have a favorable outcome with timely treatment, with normalization of liver size. Congestive hepatomegaly regresses with cardiac compensation. These scenarios demonstrate that a "large liver" is reversible if the trigger is eliminated. [62]

Infiltrative and tumor-related causes are more variable: everything depends on the nosology and stage at diagnosis. Therefore, early "signals" and rapid referral to a specialized center are so important. [63]

Overall, with a systemic approach, most patients with hepatomegaly receive an accurate diagnosis and effective care. The greatest benefit comes from a combination of lifestyle changes, risk factor management, and targeted treatment of the underlying condition. [64]

FAQ

1) "My ultrasound shows an enlarged liver, but I feel fine. Is this dangerous?"
Often, it's not. It's important to confirm normal liver size, assess risk factors, and undergo a basic screening. Further assessment is based on the results of fibrosis stratification. [65]

2) What echo signs on ultrasound indicate the cause?
Increased echogenicity and a "bright" liver indicate steatosis; dilated ducts indicate obstruction; an enlarged spleen and dilated portal vein indicate portal hypertension. Interpretation should always be made in a clinical context. [66]

3) Can liver size be reduced with "liver pills"?
There are no specific "liver-reducing" pills. Liver size is reduced by treating the underlying cause: losing weight, abstaining from alcohol, treating inflammation, and improving heart health. [67]

4) Is a biopsy always necessary?
No. In most cases, laboratory tests, ultrasound, and elastography are sufficient. A biopsy is needed in cases of diagnostic uncertainty, suspicion of alternative diagnoses, or to select specific therapy. [68]

5) How often should I be tested if I have risk factors?
Typically, annually: tests, fibrosis index, and, if necessary, elastography. The frequency depends on the initial risk and the dynamics. Discuss an individual plan with your doctor. [69]